Financial Statements of

UNIVERSITY HOSPITAL FOUNDATION



KPMG LLP 2200, 10175 – 101 Street Edmonton, AB T5J 0H3 Telephone (780) 429-7300 Fax (780) 429-7379 www.kpmg.ca

INDEPENDENT AUDITORS' REPORT

To the Trustees of University Hospital Foundation

Opinion

We have audited the financial statements of University Hospital Foundation (the Entity), which comprise:

- the statement of financial position as at March 31, 2019
- the statement of operations for the year then ended
- the statement of changes in fund balances for the year then ended
- the statement of cash flows for the year then ended
- and notes to the financial statements, including a summary of significant accounting policies (Hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements, present fairly, in all material respects, the financial position of the Entity as at March 31, 2019, and its results of operations and its cash flows for the year then ended in accordance with Canadian Accounting standards for not-for-profit organizations.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditors' Responsibilities for the Audit of the Financial Statements" section of our auditors' report.

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

Management is responsible for the other information. Other information comprises:

 the information, other than the financial statements and the auditors' report thereon, included in the Entity's annual report.

Our opinion on the financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.



In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit and remain alert for indications that the other information appears to be materially misstated.

If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in the auditors' report.

We have nothing to report in this regard as we have not obtained the information, other than the financial statements and the auditors' report thereon, included in Entity's annual report.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud
or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that
is sufficient and appropriate to provide a basis for our opinion.

The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that
 are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
 effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the
 disclosures, and whether the financial statements represent the underlying transactions and events in a
 manner that achieves fair presentation.

Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Chartered Professional Accountants

LPMG LLP

Edmonton, Canada June 26, 2019

Financial Statements

		01			
Financ	มลเ	Sta	tem	าen	ts

	Statement of Financial Position	1
	Statement of Operations and Changes in Fund Balances	2
	Statement of Cash Flows	3
	Notes to Financial Statements	4
Schedu	ules	
	Schedule 1 - Fund Balances	11
	Schedule 2 - Investment Income	25

Statement of Financial Position

As at March 31, 2019, with comparative information for 2018

	2019	2018
Assets		
Current assets:		
Cash and cash equivalents	\$ 18,506,373	\$ 16,057,098
Restricted cash (note 3)	1,587,019	1,392,663
Accounts receivable	2,575,772	159,977
Accrued interest receivable	605,554	455,703
Prepaid expenses and deposits Other assets	138,481	118,961
Other assets	 1,186,848	1,246,499
	24,600,047	19,430,901
Investments (note 4)	152,424,911	138,081,058
Equipment (note 5)	132,525	218,219
	\$ 177,157,483	\$ 157,730,178
Liabilities and Fund Balances		
Current liabilities: Accounts payable and accrued liabilities (note 6)	\$ 5,726,422	\$ 6,031,991
Current liabilities:	\$ 5,726,422 3,613,493	\$ 6,031,991 3,323,873
Current liabilities: Accounts payable and accrued liabilities (note 6)	\$	\$
Current liabilities: Accounts payable and accrued liabilities (note 6)	\$ 3,613,493	\$ 3,323,873
Current liabilities: Accounts payable and accrued liabilities (note 6) Deferred revenue Distributions payable (note 6)	\$ 3,613,493 9,339,915	\$ 3,323,873 9,355,864
Current liabilities: Accounts payable and accrued liabilities (note 6) Deferred revenue	\$ 3,613,493 9,339,915	\$ 3,323,873 9,355,864 5,079,929
Current liabilities: Accounts payable and accrued liabilities (note 6) Deferred revenue Distributions payable (note 6) Fund balances (Schedule 1): Endowment funds Externally restricted funds	\$ 3,613,493 9,339,915 2,153,394 9,323,400 108,683,490	\$ 3,323,873 9,355,864
Current liabilities: Accounts payable and accrued liabilities (note 6) Deferred revenue Distributions payable (note 6) Fund balances (Schedule 1): Endowment funds Externally restricted funds Internally restricted funds	\$ 3,613,493 9,339,915 2,153,394 9,323,400 108,683,490 20,147,081	\$ 3,323,873 9,355,864 5,079,929 10,369,120 91,772,065 15,124,613
Current liabilities: Accounts payable and accrued liabilities (note 6) Deferred revenue Distributions payable (note 6) Fund balances (Schedule 1): Endowment funds Externally restricted funds Internally restricted funds Invested in capital assets	\$ 3,613,493 9,339,915 2,153,394 9,323,400 108,683,490 20,147,081 132,525	\$ 3,323,873 9,355,864 5,079,929 10,369,120 91,772,065 15,124,613 218,219
Current liabilities: Accounts payable and accrued liabilities (note 6) Deferred revenue Distributions payable (note 6) Fund balances (Schedule 1): Endowment funds Externally restricted funds Internally restricted funds	\$ 3,613,493 9,339,915 2,153,394 9,323,400 108,683,490 20,147,081 132,525 27,377,678	\$ 3,323,873 9,355,864 5,079,929 10,369,120 91,772,065 15,124,613 218,219 25,810,368
Current liabilities: Accounts payable and accrued liabilities (note 6) Deferred revenue Distributions payable (note 6) Fund balances (Schedule 1): Endowment funds Externally restricted funds Internally restricted funds Invested in capital assets	\$ 3,613,493 9,339,915 2,153,394 9,323,400 108,683,490 20,147,081 132,525	\$ 3,323,873 9,355,864 5,079,929 10,369,120 91,772,065 15,124,613 218,219

See accompanying notes to financial statements.

On behalf of the Board:

Jim Brown

Chair, Board of Trustees

Terry Freeman

Chair, Finance & Investment

Committee

Statement of Operations and Changes in Fund Balances

Year ended March 31, 2019, with comparative information for 2018

		Endowment Funds		Externally Restricted Funds		Internally Restricted Funds		Invested in Capital Assets		Unrestricted Funds		Total 2019		Total 2018
Revenue:	\$	272.025	œ.	27 245 040	œ.		\$		\$	1 756 002	Ф С	00 472 427	¢.	20.154.019
Fundraising Lotteries	Ф	372,025	\$	27,345,019 7,189,999	Ф	-	Ф	_	Ф	1,756,093		29,473,137 7,189,999	\$	7,462,071
Realized investment income (Schedules 1 and 2) Special events		3,203		3,454,221		634,616 -		-		3,793,444 2,697,209		7,885,484 2,697,209		6,501,730 2,566,362
		375,228		37,989,239		634,616		-		8,246,746	4	7,245,829		36,684,182
Expenditures:														
Lotteries		-		4,959,897		-		-		-		4,959,897		4,893,291
Fundraising		.		679,323		-		-		3,132,836		3,812,159		3,950,272
Administrative		12,811		-		-		-		2,378,063		2,390,874		2,341,258
Special events		-		-		-		-		1,545,827		1,545,827		1,818,250
Investment costs		-		-		-		-		506,876		506,876		424,569
Amortization of equipment		-		-		-		96,225		-		96,225		103,647
		12,811		5,639,220		-		96,225		7,563,602	1	3,311,858		13,531,287
Excess (deficiency) of revenue over expenditures														
before other items		362,417		32,350,019		634,616		(96,225)		683,144	3	3,933,971		23,152,895
Unrealized gain on investments (Schedule 2)		-		-		-		-		1,546,851		1,546,851		806,468
Distributions to charitable														
organizations (note 6 and Schedule 1)		(1,408,137)		(11,510,265)		-		-		(192,631)	(1	3,111,033)	(2	24,277,983)
Excess (deficiency) of revenue over expenditures		(1,045,720)		20,839,754		634,616		(96,225)		2,037,364	2	22,369,789		(318,620)
Fund balances, beginning of year		10,369,120		91,772,065	1	5,124,613		218,219		25,810,368	14	3,294,385	1	43,613,005
Transfers		-		(3,928,329)		4,387,852		-		(459,523)		-		-
Purchase of equipment		-		-		-		10,531		(10,531)		-		-
Fund balances, end of year	\$	9,323,400	\$	108,683,490	\$ 2	0,147,081	\$	132,525	\$	27,377,678	\$ 16	5,664,174	\$ 1	43,294,385

See accompanying notes to financial statements.

Statement of Cash Flows

Year ended March 31, 2019, with comparative information for 2018

		2019		2018
Cash provided by (used in):				
Operations:				
Excess revenue / (deficiency) over expenditures Realized gains on investments Items not involving cash:	\$	22,369,789 (2,355,003)	\$	(318,620) (1,903,796)
Amortization of equipment Unrealized (gain) on investments Change in non-cash operating working capital:		96,225 (1,546,851)		103,647 (806,468)
(Increase) in accounts receivable (Increase) in accrued interest receivable (Increase) in prepaid expenses		(2,415,795) (149,850)		(103,332) (18,240)
and deposits Decrease (increase) in other assets (Decrease) increase in accounts payable		(19,520) 59,650		(24,185) (177,940)
and accrued liabilities (Decrease) increase in distributions		(305,570)		3,893,235
payable Decrease (increase) in deferred revenue		(2,926,535) 289,621		5,079,929 (122,092)
		13,096,161		5,602,138
Investments: Net (purchase) of investments		(10,441,999)		(3,682,399)
Purchase of equipment		(10,531)		(3,690,802)
Increase in cash position		2,643,631		1,911,336
Cash position, beginning of year		17,449,761		15,538,425
Cash position, end of year	\$	20,093,392	\$	17,449,761
Cash position consists of:				
Cash Cash equivalents	\$	13,008,257 5,498,116	\$	11,317,741 4,739,357
Restricted cash	Φ.	1,587,019	Φ.	1,392,663
	\$	20,093,392	\$	17,449,761

See accompanying notes to financial statements.

Notes to Financial Statements

Year ended March 31, 2019, with comparative information for 2018

1. Authority:

University Hospital Foundation (the "Foundation") operates under the Regional Health Authorities Foundations Regulation. The Foundation is a registered public charity under the Income Tax Act (Canada) and accordingly, is exempt from income taxes, provided certain requirements of the Income Tax Act are met.

The purpose of the Foundation is to seek and receive by gift, bequest, transfer or other, property of every nature and description and, subject to any prior trust conditions or other conditions imposed on the use of that property, to hold, use and administer the property to support innovation and excellence at the University of Alberta Hospital (the "Hospital"), the Mazankowski Alberta Heart Institute ("Heart Institute") and the Kaye Edmonton Clinic (the "Clinic") and affiliated programs as a center of excellence for patient care, education and research for the greater benefit of the people of Alberta and Canada.

2. Significant accounting policies:

These financial statements have been prepared by management in accordance with Canadian accounting standards for not-for-profit organizations in Part III of the CPA Canada Handbook. The Foundation's significant accounting policies are as follows:

(a) Fund accounting:

These financial statements include the following funds:

<u>Endowment funds</u> - consist of donations for which the principal is permanently restricted and undistributed investment income capitalized to principal as per the terms of reference.

<u>Externally restricted funds</u> - consist of funds, including principal and investment income, and the Foundation's share of excess of revenues over expenditures of the Full House Lottery, upon which restrictions have been imposed by the donor or external parties.

<u>Internally restricted funds</u> - consist of funds upon which restrictions have been imposed by the Board of Trustees ("Board"). These funds represent donations and income that was initially unrestricted which the Board has restricted for a specific priority program at the Hospital, Heart Institute, or Clinic.

<u>Unrestricted funds</u> - consist of donations and investment income upon which no restrictions have been imposed by the donor or the Board. These funds are managed in accordance with general Board policies, and may be restricted through Board motion.

Notes to Financial Statements (continued)

Year ended March 31, 2019, with comparative information for 2018

2. Significant accounting policies (continued):

(b) Full House Lottery:

The Foundation accounts for its interests in the Full House Lottery using the proportionate consolidation method.

(c) Cash and cash equivalents:

The Foundation considers deposits in banks, certificates of deposit and short-term investments with original maturities of three months or less as cash and cash equivalents. Restricted cash is subject to external restrictions related to the Full House Lottery.

(d) Financial instruments and risk management:

Financial instruments are recorded at fair value on initial recognition. Freestanding derivative instruments that are not in a qualifying hedging relationship and equity instruments that are quoted in an active market are subsequently measured at fair value. All other financial instruments are subsequently recorded at cost or amortized cost, unless management has elected to carry the instruments at fair value. The Foundation has elected to carry its investments at fair value.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs, which are amortized using the straight-line method.

Financial assets, measured at amortized cost, are assessed for impairment on an annual basis. If there are indicators of impairment, the carrying value of financial assets is reduced to reflect the higher of the future expected cash flows and the net realizable value. Should the impairment reverse in a subsequent period, the carrying value of the financial assets will be increased to the extent of the reversal, not exceeding the initial carrying value.

(e) Equipment:

Equipment is recorded at cost less accumulated amortization. Amortization is provided on a straight-line basis at the rate of 20% per annum.

Notes to Financial Statements (continued)

Year ended March 31, 2019, with comparative information for 2018

2. Significant accounting policies (continued):

(f) Revenue recognition:

Under the restricted fund basis of accounting for contributions, revenue is recognized as follows:

- (i) Contributions for general operations and unrestricted contributions are recognized as revenue of the unrestricted funds in the year received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured. All restricted contributions are recognized as revenue of the externally restricted funds in the year.
- (ii) Contributions for endowment are recognized as revenue in the Endowment Funds.
- (iii) Investment income earned on endowment funds that must be used in accordance with the conditions imposed by the donor is recognized as revenue of the externally restricted funds. Investment income earned on endowment funds that must be added to the endowment principal is recognized as revenue of the endowment fund. Unrestricted investment income earned on endowment funds is recognized as revenue of the unrestricted funds. Other investment income is recognized as revenue of the unrestricted funds when earned.
- (iv) Lottery and special events revenue are recognized as of the date of the lottery prize draw or event as Lottery or event revenues cannot be reasonably estimated until the date of the lottery prize draw or event.
- (g) Contributed materials and services:

Contributed materials and services are recorded at fair value when they would have otherwise been purchased and when a fair value can be reasonably estimated. Contributed services of volunteers are not recognized in these financial statements as their fair value cannot be reasonably determined.

(h) Allocation of fundraising and general expenses:

The Foundation classifies expenses on the Statement of Operations and Changes in Fund Balances by function and does not allocate expenses between functions.

(i) Use of estimates:

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenue and expenditures during the period. Actual results could differ from these estimates.

Notes to Financial Statements (continued)

Year ended March 31, 2019, with comparative information for 2018

3. Full House Lottery joint venture:

These financial statements include the Foundation's proportionate share (50%) of the Full House Lottery as follows:

	2019		2018
Assets			
Restricted cash	\$ 1,587,019	\$	1,392,663
Accounts receivable	87,651		103,321
Other assets*	1,186,848		1,246,499
	\$ 2,861,518	\$	2,742,483
Liabilities and Net Deficiency			
Accounts payable and accrued liabilities	\$ 406,944	\$	673,062
Deferred revenue**	3,613,493	·	3,323,873
	4,020,437		3,996,935
Net deficiency	(1,158,919)		(1,254,452)
	\$ 2,861,518	\$	2,742,483
	2019		2018
Revenue	\$ 7,189,999	\$	7,462,071
Expenditures	4,959,897		4,893,291
Partner allocation	2,134,569		2,454,603
Excess of revenue over expenditures and distributions	95,533		114,177
Cash from operating activities	1,489,467		1,343,833

^{*}Other assets include lottery prizes that will be awarded subsequent to the draw date of July 5, 2019 (2018 – July 6, 2018)

During the year the Foundation bought a home from the Full House Lottery that was not chosen as the 2nd grand prize home, with the intention to resell the home on the open market. The proceeds of the sale to the Foundation were \$599,897 (2018 - \$597,741) and are recorded under Fundraising revenues. The costs to purchase and sell the home was \$624,261 (2018 - \$642,879) and is recorded under Fundraising expenditures. This resulted in a net loss to the Foundation of \$24,364 (2018 - \$45,138).

^{**}Lottery revenues and expenses are deferred until the draw date of July 5, 2019 (2018 – July 6, 2018)

Notes to Financial Statements (continued)

Year ended March 31, 2019, with comparative information for 2018

4. Investments:

	2019	2018
Bonds		
Pooled Bond Funds	1,927,618	1,533,224
Government of Canada bonds	18,811,042	17,457,432
Provincial bonds	20,911,459	18,341,630
Municipal bonds	1,905,633	1,727,937
Corporate bonds	28,537,949	26,010,269
Total bonds	72,093,701	65,070,492
Equities		
Canadian common shares	18,453,856	16,621,609
Mutual funds		
Canadian mutual funds	3,758,824	3,942,582
United States mutual funds	28,545,129	23,989,950
International mutual funds	29,427,733	28,305,615
Total mutual funds	61,731,686	56,238,147
Cash surrender value of life insurance policies	145,669	150,810
	\$ 152,424,912	\$ 138,081,058

Face value of the bonds is \$63,959,389 (2018 - \$59,808,000) of which 2.79% (2018 - 0.02%) mature within the next fiscal year and 56.07% (2018 - 46.31%) mature within the next five years.

The Foundation believes it is not exposed to significant liquidity risk as all investments are held in instruments that are highly liquid and can be disposed of to settle commitments. The fixed income securities yield interest between 1.25% and 10.00% and have maturities ranging from 2019 to 2048.

5. Equipment:

	2019	2018
Equipment Less accumulated amortization	\$ 1,237,979 (1,105,454)	\$ 1,227,448 (1,009,229)
Net book value	\$ 132,525	\$ 218,219

Notes to Financial Statements (continued)

Year ended March 31, 2019, with comparative information for 2018

6. Related party transactions:

The Foundation provides donations of money and gifts in kind to the Hospital, Heart Institute and Clinic. These donations allow the Hospital, Heart Institute and Clinic to provide equipment, patient services, education and research not funded from other sources. The cash donations are included in distributions to charitable organizations.

Accommodation and certain overhead costs incurred in the administration of the Foundation, borne by the Hospital, Heart Institute and Clinic, are not recorded in these financial statements as the value of the services is not readily determinable.

At March 31, 2019, accounts payable and accrued liabilities includes \$380,901 (2018 - \$346,324) payable to Alberta Health Services ("AHS") for certain salaries and services paid by AHS on the Foundation's behalf as well as distributions to the Hospital, Heart Institute and Clinic in support of research and patient care programs. These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

During the year ended March 31, 2019, the Foundation distributed \$13,111,033 (2018 - \$24,277,983) to the Hospital, the Heart Institute and Clinic, the University of Alberta, and other charitable organizations. During the previous fiscal year, the Foundation accrued a large distribution of \$9,433,088 for payment over the next two fiscal years. Of this amount, \$7,279,694 was paid to AHS during the fiscal year and \$2,153,394 (2018 - \$5,079,929) remains recorded in distributions payable as at March 31, 2019.

7. Additional information to comply with the disclosure requirement of the Charitable Fund Raising Act and Regulation:

In fiscal 2019, \$2,093,416 (2018 - \$1,909,880) was paid as remuneration to employees whose principal duties involve fundraising.

8. Pledge commitments:

The Foundation has received signed pledge agreements in the amount of \$15,247,855 (2018 - \$5,951,167) from donors which have not been recognized as revenue at year-end. Payment of the amounts pledged is expected by the Foundation as follows:

	2020	2021	2022	Thereafter
Prostate Health Clinic Brain Centre Campaign Hospital	\$ 1,045,000 1,421,000 583,333	\$ 1,045,000 846,000 150,000	\$ 1,045,000 716,000 30,000	\$ 6,020,000 2,346,522
Total	\$ 3,049,333	\$ 2,041,000	\$ 1,791,000	\$ 8,366,522

Notes to Financial Statements (continued)

Year ended March 31, 2019, with comparative information for 2018

9. Funding commitments:

The Foundation has the following cumulative funding commitments, as approved by the Board, which are expected to be fulfilled within the next three years:

	2019	2018
Brain Centre Campaign Hospital Heart Institute Prostate Health Clinic	\$ 7,909,045 21,324,809 2,165,000 1,164,947	\$ 2,795,331 10,326,008 1,756,131 1,164,947
	\$ 32,563,801	\$ 16,042,417

10. Financial risk:

Income and financial returns on investments are exposed to credit and price risks. Credit risk relates to the possibility that a loss may occur from the failure of another party to perform according to the terms of the contract. Price risk is comprised of interest rate, foreign exchange and market risk. Interest rate risk relates to the possibility that the investments will change in value due to future fluctuations in market interest rates. Foreign exchange risk relates to the possibility that the investments will change in value due to fluctuations in foreign currencies. Market risk relates to the possibility that the investments will change in value due to future fluctuations in market prices.

These risks are mitigated by the Foundation's investment policies, which prescribe the investment asset mix including the degree of liquidity and concentration and the amount of foreign content.

Changes in interest rates and credit ratings are the main cause of changes in the fair value of government securities and corporate bonds resulting in a favorable or unfavorable variance compared to book value. Credit risk is mitigated by investing in securities such that an average credit rating of A or better is achieved and diversifying the securities between government, government backed and corporate issuers. Interest rate risk is mitigated by managing maturity dates and payment frequency. The Foundation limits credit risk associated with other financial assets by dealing with counterparties that it believes are creditworthy.

The Foundation does not use derivative instruments to alter the effects of interest, market and foreign exchange risks.

Schedule 1 - Fund Balances

	Opening Balance	(Current year		Closing Balance
	March 31, 2018	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2019
UNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARC	H & EDUCATION				
<u>Arthritis</u>					
Hugh H. & Annabelle C. Millar Fund for Arthritis Research	645,664	29,055	-	-	674,719
Betty B. Drury Fund in support of Rheumatology	629,825	28,342	-	-	658,167
Dr. Donald Stanley Special Purpose Fund for Clinical Research in Rheumatoid Arthritis	83,458	3,756	-	-	87,214
Total Arthritis Funds	1,358,947	61,153	-	-	1,420,100
Brain Centre					
UHF Brain Centre Campaign Fund	5,519,006	445,807	-	4,387,852	10,352,665
University Hospital Foundation Board Fund	1,074,032	48,331	-	_	1,122,364
Mildred I. Olsen Fund for Neurology Research	996,489	44,842	_	-	1,041,331
Dr. Rowland & Muriel Haryett Fund for Innovation in Neurosciences	1,650,106	37,666	-	(813,085)	874,687
Allan H. Owen & Family Stroke Chair Fund	1,167,284	35,158	_	(385,990)	816,453
James & Jeanie Brown ALS Innovation Education & Research Fund	989,729	22,042	199	(500,000)	511,970
E. (Ben) & Mary Hochhausen Fund for Epilepsy & Cerebral Palsy Research	429,618	18,077	9,742	(30,678)	426,758
Dennis M. Erker Parkinson's Innovation & Research Fund	332,558	11,122	20,000	(102,000)	261,680
Wismer Fund in support of Myasthenia Gravis	217,246	9,878	6,410	-	233,535
Multiple Sclerosis Outreach Wellness Navigator Fund	392,965	4,943	-	(283,111)	114,797
Anne Iris Reiser Fund in support of Research & Treatment of Brain Disorders & Diseases	-	1,862	100,000	-	101,862
George & Eileen Smith Brain Innovation Fund	11,512	2,386	50,000	-	63,898
Marjorie Lewis Cable Medical Research Memorial Fund	58,581	2,470	-	(3,699)	57,352
Lyle Hawkins Fund in support of Alzheimer's Disease Research	50,953	2,293	-	-	53,246
United Parkinson's Disease Research & Patient Care Fund	48,572	2,199	1,000	-	51,771
H.W. Skaret Endowment Fund	47,902	1,873	1,000	(6,560)	44,214
Evelyn Harkness McKenzie Fund for Parkinson's Disease Research	32,094	1,341	-	(2,303)	31,131
Judy Laviolette Memorial Fund in support of Neurology	24,820	1,117	-	-	25,937
Carolyn Ann MacDonald Fund	23,210	1,044	-	-	24,254
Reddon-Valens MS Research Fund	20,266	847	-	(1,454)	19,658
Douglas Arthur Pettitt Memorial Fund in support of Research & Patient Care for Ehlers Danlos Syndrome	17,358	781	-	-	18,139
Mei Lee Fung Memorial Fund for Treatment, Research & Prevention of Stroke	13,247	553	-	(951)	12,850
Total Brain Centre Funds	13,117,546	696,633	188,351	2,258,020	16,260,550

Schedule 1 - Fund Balances (continued)

	Opening Balance	(Closing Balance	
	March 31, 2018	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2019
UNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARC	H & EDUCATION (c	ontinued)			
Burn Unit					
Firefighters' Burn Camp Established Fund	592,687	26,671	_	_	619,358
Harold & Emilie Tucker Memorial Fund	231,949	9.708	702	(16,616)	225,743
Alfred Drader Fund	158,056	6,602	-	(11,341)	153,317
Firefighters' Burn Unit Treatment, Patient Care & Education Fund	392,624	1,198	142,212	(440,000)	96,034
George A. Taylor Memorial Fund	8,980	375	-	(644)	8,711
Total Burn Unit Funds	1,384,297	44,554	142,914	(468,602)	1,103,163
<u>Cancer</u>					
Allard Foundation Cancer Research Fund	1,633,161	66,742	-	(150,000)	1,549,903
Ria & Cory Wild Fund for Childhood Cancer Research	385,547	17,350	-	-	402,897
Wesley C. Stone Fund for Cancer Research	197,001	8,865	-	-	205,866
Ida Hoffman Cancer Research Fund	179,951	7,517	-	(12,912)	174,556
Frederick T. Jenner Memorial Scholarship Fund for Cancer Research & Education	154,664	6,960	-	-	161,624
Eileen Nash Memorial Fund created by Kathy & Ross Grieve	136,123	6,126	-	-	142,249
Katherine Laschowski Fund for Cancer Research	52,501	2,363	-	-	54,863
Mary Talbot Memorial Fund for Cancer Research	43,450	1,955	-	-	45,406
Dr. W.W. Burnett Memorial Fund for Bone Cancer Education & Research	11,856	534	-	-	12,389
Total Cancer Funds	2,794,253	118,410	-	(162,912)	2,749,752
<u>Diabetes</u>	4.000.047	57.040			4.00=.004
C.F. "Curly" & Gladys MacLachlan Fund for Islet Molecular Biology & Islet Transplantation	1,280,211	57,610	-	-	1,337,821
Laboratories in support of Diabetes Mellitus Research	400.004	00.000			E40.054
Paddy & Ken Webb & Family Fund in support of Diabetes Mellitus Research	490,291	22,063	-	-	512,354
William H. (Pete) & June Johnson Memorial Fund in support of Pediatric Diabetes	63,658	3,035	6,000	-	72,693
Research & Care	0.004	240			7.004
Bud & Joyce Byram Fund for Diabetes Research Total Diabetes Funds	6,891 1,841,052	310 83,017	6.000	- -	7,201 1,930,069

Schedule 1 - Fund Balances (continued)

	Opening Balance		_	Closing Balance	
	March 31, 2018	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2019
UNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARCH	& EDUCATION (c	continued)			
Equipment					
Anonymous Fund in support of High Priority Equipment Needs	586,744	25,360	91,964	(66,655)	637,412
Fred & Mil Vincett Fund in support of Patient Care Equipment	156,519	7,043	-	-	163,563
J. Gordon & Millicent C. McDonald Memorial Fund in support of High Priority Patient Care Equipment	38,575	1,736	-	-	40,31
Frances R. Bundle Memorial Fund	15,242	686	-	-	15,928
Albert Michael & Phyllis Mary Mort Fund in support of High Priority Equipment	3,465	156	-	-	3,62
Total Equipment Funds	800,545	34,981	91,964	(66,655)	860,835
<u>Gastroenterology</u>					
eRoy & Karen Sonnenberg Fund to support Fecal Microbiota Transplantation	315,268	13,958	50,000	(17,412)	361,81
Robert & Shirley Stollery Fund for Inflammatory Bowel Disease Education & Research	78,662	3,286	-	(5,644)	76,30
ack & Zita Rosen Fund in support of Gastroenterology	32,502	1,358	-	(2,332)	31,52
Villiam F. Lede Fund for the Gastroenterology Fellowship Program	26,122	1,091	-	(1,874)	25,33
aul Bowlen Liver – Dr. R.H. Wensel Trust Fund for a Visiting Professorship in Hepatology	11,125	465	-	(798)	10,79
ohn Berezon – Dr. R.H. Wensel Trust Fund for Gastroenterology Education	7,849	328	-	(563)	7,61
otal Gastroenterology Funds	471,529	20,485	50,000	(28,624)	513,3
<u>Genetics</u>					
Iniversity Hospital Foundation Fund for Medical Genetics	861,840	36,000	-	(61,840)	836,00
Gilbert K. Winters Fund in support of Severe Infant Skeletal Deformity	549,962	22,973	-	(39,462)	533,47
otal Genetics Funds	1,411,802	58,973	-	(101,302)	1,369,47

Schedule 1 - Fund Balances (continued)

	Opening Balance	(Current year	_	Closing Balance
	March 31, 2018	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2019
UNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARC	H & EDUCATION (c	ontinued)			
Medical Research Competition					
Eric & Helena Douglass Fund in support of Clinical Research	2,453,023	102,465	-	(176,013)	2,379,475
Stanley E. Robins Special Purposes Medical Research Fund	1,826,686	78,102	-	(91,094)	1,813,693
Muriel Robins Fund for Clinical Research	821,475	35,375	-	(35,366)	821,484
Gary Rees Garson Medical Research Fund	515,487	21,539	330	(36,977)	500,37
Jniversity Hospital Foundation Board Fund	263,204	10,994	-	(18,886)	255,31
Ruth Robertson Memorial Fund in support of Heart & Cancer Research	233,446	10,128	-	(8,376)	235,19
Don & Mary Cunningham Fund for Clinical Research	218,423	9,124	-	(15,673)	211,87
King H. Mok Fund in support of Medical Research	190,912	8,135	6,000	(13,683)	191,36
George & Margaret McNeill Fund	169,704	7,256	7,538	(12,024)	172,47
Marcia & Dorothy May Hallett Special Purpose Fund	171,392	7,159	-	(12,298)	166,25
Lillian Doris Nielsen Fund in support of Diabetes, Pediatric Research, Cardiac & Stroke	127,708	5,335	-	(9,163)	123,87
Projects or Programs					
Nilliam & Betty Rathje Fund for Heart & Cancer Research	106,736	4,476	-	(7,278)	103,93
Antonio & Angelina Biamonte Clinical Research Memorial Fund	101,131	4,224	-	(7,256)	98,09
Sophie Buttner Fund in support of Medical Research	55,042	2,299	-	(3,949)	53,39
Katrina Witwicky Memorial Fund for Clinical Research	53,749	2,245	-	(3,857)	52,13
sabella Tulloch Memorial Fund	52,540	2,195	-	(3,770)	50,96
rene Samuel Fund	48,008	2,005	-	(3,445)	46,56
Ross & Gwen Harris Fund for Clinical Research	44,049	1,857	1,500	(3,161)	44,24
ohn Antku Fund	15,021	627	-	(1,078)	14,57
Agnes Y. Fleming Special Purpose Fund to Enrich Medical Research	11,250	470	-	(807)	10,91
Villiam H. Roxburgh Memorial Fund	6,000	251	-	(431)	5,82
lary Allardyce Cross Endowment Fund	3,890	164	-	(235)	3,82
Diga Pond Fund	308	14	-	- '	32
Total Medical Research Competition Funds	7,489,185	316,440	15,368	(464,820)	7,356,17

Schedule 1 - Fund Balances (continued)

	Opening Balance Current year				Closing Balance
	March 31, 2018	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2019
UNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARCH	4 & EDUCATION				
Medicine					
Marshall Eliuk Fund for Exemplary Care in Hematology	806,953	48,793	1,000,000	(35,000)	1,820,745
Muhlenfeld Family Trust Fund	1,562,085	42,750	-	(612,085)	992,750
Canadian Biomaterials Society - Alberta Student Chapter Education Fund	45,428	1,909	-	(3,000)	44,338
Mary M. Bekker Fund in support of Adult Orthopedic Nursing	32,813	1,477	-	-	34,290
Charles McDougall & Sandra Versteeg-McDougall Fund for Senior Urology Resident Award	29,809	1,251	-	(2,000)	29,060
Patricia D. Yates & Arthur D.G. Yates Fund in support of Adult Orthopedic Medicine	36,062	899	-	(16,074)	20,887
Total Medicine Funds	2,513,149	97,079	1,000,000	(668,159)	2,942,070
Mental Health					
Psychiatry Research Fund	695,196	31,284	-	-	726,480
Anonymous Fund for Study, Research & Treatment of Mental Illness	610,951	23,628	-	(85,895)	548,684
Simon & Martina Sochatsky Fund for Menatal Health Research & Patient Care	81,117	3,774	9,049	-	93,940
Howard Berger Memorial Schizophrenia Research Fund	55,307	2,489	-	-	57,796
Abraham & Freda Berger Memorial Fund in support of Psychiatric Research	34,326	1,328	-	(4,826)	30,828
Total Mental Health Funds	1,476,898	62,502	9,049	(90,721)	1,457,728
Nephrology					
Matt & Betty-Jean Baldwin Home Hemo Fund in support of the Home Hemodialysis	1,092,809	49,176	-	-	1,141,985
Program					
Allan Wallace Peterson Fund for Kidney related Research & Equipment	38,369	1,727	-	-	40,095
Ronald & Arda Baltzan Fund for Kidney Research	15,400	693	-	-	16,093
Total Nephrology Funds	1,146,577	51,596	-	-	1,198,173

Schedule 1 - Fund Balances (continued)

	Opening Balance	(_	Closing Balance	
	March 31, 2018	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2019
		4 D			
UNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARCH	H & EDUCATION (C	ontinued)			
Nursing Education					
Ruth A. (Poole) Van Dusen Memorial Fund for Nursing Scholarships funded by John E. & Barbara Poole Family	420,597	18,657	-	(6,000)	433,254
James Yi & Wei Chiwei Fund for Nursing Scholarships	279,974	12,261	-	(7,500)	284,735
Elisabeth Palate Nursing Education Fund	169,819	7,713	10,000	(1,000)	186,532
University Hospital Foundation Nursing Scholarships Fund	62,176	2,550	-	(5,500)	59,226
Brenda Moffitt Memorial Fund in support of Nursing Education	41,665	1,875	-	-	43,540
Michael J. Lahey Nursing Scholarship Fund	29,010	1,305	-	-	30,315
Dr. Robert M. Shaw Memorial Fund	28,153	1,222	-	(1,000)	28,375
Judy (Patmore) Klaczek Memorial Fund in support of Nursing Education	26,800	1,161	-	(1,000)	26,961
Total Nursing Education Funds	1,058,192	46,745	10,000	(22,000)	1,092,937
<u>Ophthalmology</u>					
Olive Young Special Purpose Fund for Ophthalmology Research	315,356	14,191	-	-	329,547
The Catherine McLean Fund in support of Ophthalmology	198,062	8,913	-	-	206,975
Total Ophthalmology Funds	513,418	23,104	-	-	536,522
Patient Compassionate Support					
Wilbur & Marjorie Bowker Compassionate Support Services Fund	314,411	14,151	50	-	328,611
Kultgen-Lees Memorial Fund for Maintenance & Care of Patients with Acquired Immune	202,945	8,683	-	(10,000)	201,627
Deficiency Syndrome					
Anonymous Foundation Compassionate Support Fund	137,776	6,200	-	-	143,976
Anonymous Compassionate Support Fund	68,888	3,100	<u>-</u>	<u> </u>	71,988
Total Patient Compassionate Support Funds	724,020	32,133	50	(10,000)	746,203

Schedule 1 - Fund Balances (continued)

	Opening Balance		Current year		Clos	ing Balance
	March 31, 2018	Allocated Investment Income	Donations	Distributions and Transfers	Marc	ch 31, 2019
UNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARC	H & EDUCATION	(continued)				
Pediatrics						
Stjepan Posavec Fund to benefit Children with Physical Handicaps	103,303	4,649	-	-		107,95
Michaell Shirvell Griffin Memorial Fund	69,921	3,204	5,000	-		78,12
Total Pediatrics Funds	173,224	7,852	5,000	-		186,07
<u>Pulmonary</u>						
gnes D. Lynch Fund for the Respiratory Outreach Centre	485,530	21,849	-	-		507,37
Pulmonary Division Research & Academic Fund to support all Academic Activities within he Division of Pulmonary Medicine	110,979	4,382	-	(13,612)		101,74
Egerton W. King Fund for Childhood Asthma Research	94,116	4,235	-	-		98,35
Dr. Brian Sproule Fund for Education & Research in Pulmonary Medicine	65,633	2,538	-	(9,227)		58,94
Dr. D. Young Memorial Fund for Visiting Speakers of the Lung Transplantation Program	30,848	1,388	-	-		32,23
Thyra Parker Special Purpose Fund for Cystic Fibrosis Research	20,284	783	-	(2,888)		18,17
Total Pulmonary Funds	807,390	35,175	-	(25,727)		816,83
<u>Surgery</u> James Yi & Wei Chiwei Fund in support of the General Surgery Residents' Retreat	204,034	8,523	-	(14,640)		197,91
<u>Transplantation</u> S. Jean Milner Fund for Continuing Education & Research in Thoracic Organ	555,815	25,012	-	-		580,82
Fransplantation						
The Lung Transplant Rehabilitation Education & Research Fund	273,594	13,188	34,000	-		320,78
Klaus & Helga Rieder Fund for Kidney Transplant Research & Education	97,177	4,488	10,000	-		111,66
Or. Harald & Dr. Berta Kuckertz in support of Organ Transplant Research	58,170	2,618	-	-		60,78
Fotal Organ Transplantation	984,756	45,305	44,000	-		1,074,06
TOTAL UNIVERSITY OF ALBERTA HOSPITAL	\$ 40.270.815	\$ 1.844.659	\$ 1.562.696	\$ 133.858	\$	43.812.0

Schedule 1 - Fund Balances (continued)

	Opening Balance		Closing Balance		
	March 31, 2018	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2019
MAZANKOWSKI ALBERTA HEART INSTITUTE - PATIENT CARE, RESEARCH & EDUCA	ATION				
Cardiac Sciences					
MacDonald Cardiac Sciences Talent & Technology Fund	1,149,181	181,505	10,000,500	(129,616)	11,201,570
Stuart & Winona Davis Fund in support of Mazankowski Alberta Heart Institute	6,784,346	305,296	-	-	7,089,641
Dr. Arvind Koshal Advancement Fund	3,385,346	138,874	2,500	(300,000)	3,226,720
Jose Luis & Dina Arrese Goicoa Fund in support of the Mazankowski Alberta Heart Institute	1,942,181	87,398	-	-	2,029,579
Gerald Averback Medical Research Fund	1,904,374	85,697	-	-	1,990,071
Robert Marko Memorial Fund in support of the Mazankowski Alberta Heart Institute	1,377,763	61,999	-	-	1,439,763
William H. (Bill) Caine & Terry M. Caine Fund	850,135	38,256	-	-	888,391
Dr. Rowland & Muriel Haryett Fund for Cardiac Surgery Clinical Innovation	752,308	26,503	-	(163,343)	615,468
Richard E. Rossall Arrhythmia & Valvular Heart Disease Academic Trust Fund	529,766	23,839	-	-	553,606
Lyle & Kathryn Abraham Fund in support of the Mazankowski Heart Institute	251,354	11,560	20,000	-	282,914
Pearl & Armand Nielsen Fund in support of Cardiac Surgery	205,179	9,843	25,000	-	240,023
Lawrence & Shirley Henderson Fund in support of Cardiology	152,566	7,996	70,000	-	230,562
Greg & Aurdrey Greenough Cardiac Sciences Fund in Memory of Dr. Norman Davies	183,395	8,253	-	-	191,647
Dr. Neil Duncan/Children's Heart Society Fund for Pediatric Cardiology	144,002	6,269	-	(4,700)	145,571
Rick Cormier Memorial Fund in support of the Mazankoski Alberta Heart Institute	79,471	3,576	-	-	83,047
Ryan Tiltgen Memorial Fund for Pediatric Cardiology	75,665	3,405	-	-	79,070
Ray & Joan Joberty Fund in support of the Mazankowski Alberta Heart Institute	40,216	1,862	2,000	-	44,078
Martin & Carlene Stoklossa Fund for Cardiac Patient & Family Care	35,278	1,604	4,500	-	41,382
Mary & George Shreeves Fund for the Advancement of Cardiac Sciences	35,841	1,631	1,000	-	38,473
Ron Skuba Arrhythmia Research Fund	28,882	1,315	600	-	30,797
Pediatric Cardiology Training Fund	19,192	864	-	-	20,055
Matilda (Kelly) Poirier Fund in support of Research in the Heart Transplant Program	7,668	345	-	-	8,013
Total Cardiac Sciences Funds	19,934,109	1,007,891	10,126,100	(597,660)	30,470,440

Schedule 1 - Fund Balances (continued)

	Opening Balance	(Closing Balance		
	March 31, 2018	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2019
MAZANKOWSKI ALBERTA HEART INSTITUTE - PATIENT CARE, RESEARCH & EDU	JCATION (continued)				
Cardiac Sciences - Research					
Heart Function Fund	-	-	1,000,000	-	1,000,000
Dr. Joseph Dvorkin Memorial Fund for Cardiology Education & Research	189,575	8,531	-	-	198,105
Nick & Margret Oneschuk Fund in support of Cardiac Research	113,199	4,728	-	(8,122)	109,805
Olga Pollock Fund in support of Heart & Stroke Research	105,609	4,411	-	(7,578)	102,443
Total Cardiac Sciences - Research	408,382	17,671	1,000,000	(15,700)	1,410,353
Cardiovascular & Thoracic Surgery (John Carter Callaghan Chair)					
University Hospital Foundation Board Fund	519,490	23,377	-	-	542,867
Anonymous Fund	450,810	20,286	-	-	471,096
George E. Mucha Fund	119,868	5,430	2,500	-	127,798
John G. Mucha Family Trust	101,007	4,563	2,500	-	108,070
Robert & Shirley Stollery Fund	97,399	4,383	-	-	101,782
Benny & Olga Elkow Fund	49,510	2,265	2,000	-	53,775
Nelson Lumber Foundation Fund	51,444	2,315	-	-	53,759
Greg & Audrey Greenough Fund	45,883	2,065	-	-	47,948
Irene Dyck Memorial Fund	29,921	1,346	-	-	31,267
Joe Check Fund	27,135	1,221	-	-	28,356
Lawrence & Luiba Trahan Fund	19,224	865	-	-	20,089
Alvin & Mona Libin Fund	18,031	811	-	-	18,843
Ray & Joan Joberty Fund	11,502	518	-	-	12,019
Helene Girard Fund	9,122	410	-	-	9,532
Mildred I. Olsen Fund	8,632	388	-	-	9,020
Reuben & Goldie Cipin Fund	6,559	295	-	-	6,854
Joe & Dolores Bruchal Special Purpose Fund for Cardiovascular Surgery Education & Research	2,064	93	-	-	2,157
Total Cardiovascular & Thoracic Surgery	1,567,600	70,633	7,000	-	1,645,233

Schedule 1 - Fund Balances (continued)

	Opening	Balance			Cui	rrent year			Clo	sing Balance
	March 31, 2018		l	Allocated Investment Income		Donations	Distributions ns and Transfers		Ma	arch 31, 2019
KAYE EDMONTON CLINIC - PATIENT CARE, RESEARCH & EDUCATION										
Family Medicine Dr. Scott McLeod Family Medicine Memorial Fund funded by John & Barbara Poole Family		972,975		43,784		-		-		1,016,759
Kaye Edmonton Clinic The Kaye Fund Prostate Innovation Fund Dianne & Irving Kipnes Urology Centre Innovation & Research Fund	,	007,842 473,312 -		658,090 201,602 18,616		24,250 13,333 1,000,000		(385,618) - -		15,304,564 4,688,247 1,018,616
Total Kaye Edmonton Clinic	19,	481,153		878,307		1,037,583		(385,618)		21,011,426
TOTAL KAYE EDMONTON CLINIC	\$ 20	,454,128	\$	922,091	\$	1,037,583	\$	(385,618)	\$	22,028,185
HIGHEST PRIORITY / GENERAL PURPOSE										
Festival of Trees Fund R. John & Agnes M. Adams Fund Al & Wendy Bryan Fund for the Annual Campaign John Romanchuk Fund Capital Packers Inc./Komarnicki Family Fund B. Martha Moritz Fund Roger & Peggy Gouin Fund		129,225 266,710 227,432 199,164 153,360 166,019 145,173		50,239 11,214 9,670 8,177 7,060 6,683 6,533		- 7,213 250 10,000 -		(12,811) (17,500) (17,500) (17,500) - (17,500)		1,166,652 260,425 226,815 190,091 170,420 155,202 151,706
Albert Drews Fund William Kenneth Drake Fund Reinhard Henschel Fund Frances Olson Special Purpose Fund for the Annual Campaign Richard & Trudy Cormier Fund Ada & Fred Carpenter Fund Donald & Betty Carlson Fund Garry & Joyce Rathgeber Fund Leo S. & Doris E. Hester Memorial Fund Winnifred Henning Fund		155,186 132,638 131,572 125,910 116,259 112,172 105,404 99,627 93,542 89,384		6,196 5,969 5,921 5,666 5,232 5,048 4,743 4,523 4,209 4,022		3,000		(17,500)		143,882 138,606 137,493 131,576 121,491 117,220 110,147 107,150 97,751 93,406
Helen Nemirsky Memorial Fund		83,705		3,809		3,000		-		90,514

Schedule 1 - Fund Balances (continued)

	Opening Balance	(Current year		Closing Balance
	March 31, 2018	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2019
HIGHEST PRIORITY / GENERAL PURPOSE (continued)					
Bill & Betty Sinclair Fund	80,120	3,605	-	_	83,725
Cecille Shtabsky Special Purpose Fund for the Annual Campaign	76,963	3,463	-	-	80,426
Beuerlein Estate & Maguire Trust for the Annual Campaign	75,493	3,397	-	-	78,891
Walter Louis Batke Fund	67,684	3,046	-	-	70,730
Anonymous Fund	41,765	1,879	-	-	43,644
Elizabeth & Clarence Preitz Fund	36,041	1,622	-	-	37,663
Isidor & Grace Gliener Fund	34,030	1,531	-	-	35,562
John & Mary Sterenberg Fund	31,162	1,443	2,665	-	35,270
Alex Romaniuk Memorial Fund	33,711	1,517	-	-	35,228
Machum Family Fund	32,872	1,495	1,500	(1,000)	34,868
Thomas Rhatigan Fund for the Annual Campaign	33,188	1,493	-	-	34,682
Leonard Vernon Kallis General Purpose Fund	33,160	1,492	-	-	34,652
T.S. & Mary Wilson Fund	30,051	1,352	-	-	31,403
Florence Thomas Fund for the Annual Campaign	27,305	1,229	-	-	28,534
Shenaz & Azim Jeraj Special Purpose Fund	23,534	1,059	-	-	24,593
Janelle Newton Fund	16,423	739	-	-	17,162
Bryan & Kathy O'Donnell Fund	15,706	707	-	-	16,412
Jack & Audrey Holmes Fund	15,301	689	-	-	15,989
Bernard Marvin Sheehan Memorial Fund	14,495	652	-	-	15,148
Donald R. & Elizabeth B. Brandt Fund	13,392	603	-	-	13,995
Jessie W. Templeman Fund	13,389	603	-	-	13,992
Gordon Cameron Fund	10,642	479	-	-	11,120
Rick & Nikki Vogel Special Purpose Fund	9,038	407	-	-	9,444
Gail & Harold Taylor Fund	6,890	310	-	-	7,200
Maria Adrienne Orn Fund	6,650	299	-	-	6,950
To Ha & Hung Diep Dang Fund in support of High Priority Equipment	-	1	3,200	-	3,201
Total Highest Priority / General Purpose Funds	4,311,486	190,027	30,828	(101,311)	4,431,030

Schedule 1 - Fund Balances (continued)

	Opening Balance		Current year		Clo	sing Balance
	March 31, 2018	Allocated Investment Income	Donations	Distributions and Transfers	Ma	arch 31, 2019
SPECIAL PURPOSE						
Dow Hicks Fund in support of Transplant Programs & Medical Research	1,902,086	85,594	_	-		1,987,680
Chint Kaur Lali & Boota Singh Lali Endowment Fund	294,727	13,306	1,000	-		309,033
Dr. R.E. Bell Memorial Fund for a Visiting Professor	176,559	7,549	10,562	(12,179)		182,492
Dorothy & Walter Mackenzie Memorial Fund	167,281	7,594	5,000	- 1		179,875
Dr. Claude V. Jamieson & Dr. Heber C. Jamieson Memorial Fund in support of the Nuclear Magnetic Resonance Research Centre	73,518	3,308	-	-		76,827
Jacoba Vanthof Fund in support of Diabetes & Cardiac Research	58,875	2,649	_	-		61,524
Dr. Robert James Kelly Global Health Memorial Fund	61,232	2,620	_	(3,000)		60,852
Tevie & Arliss Miller Fund in support of the Bioethics Centre	35,621	1,603	-	-		37,224
Dr. Lorne Tyrrell Board Restricted Fund to support the Tyrrell Lectureship in Medical Microbiology & Immunology	23,121	1,040	-	-		24,161
Adrash Gopal Education & Research Fund	10,064	563	5,000	-		15,626
Total Special Purpose Funds	2,803,083	125,827	21,562	(15,179)		2,935,294
TOTAL ESTABLISHED FUNDS	\$ 89,749,604	\$ 4,178,800	13,785,769	\$ (981,610)	\$	106,732,564
		Non-Establish	ed Internally Re	estricted Funds		4,781,963
		Non-Establishe	ed Externally Re	stricted Funds		30,374,879
		Non-E	stablished Unre Invested ii	estricted Funds n capital assets		23,642,243 132,525
				Total net assets		165,664,174

Schedule 2 - Investment Income

	End	dowment Funds	Externally Restricted Funds	Internally Restricted Funds	Į	Jnrestricted Funds	Total 2019	Total 2018
Interest Dividends Realized gains	\$	3,203	\$ 3,454,221 - -	\$ 634,616 - -	\$	968,585 469,856 2,355,003	\$ 5,060,625 469,856 2,355,003	\$ 4,155,609 442,325 1,903,796
Realized investment income		3,203	3,454,221	634,616		3,793,444	7,885,484	6,501,730
Unrealized (loss) gain		-	-	-		1,546,851	1,546,851	806,468
Total	\$	3,203	\$ 3,454,221	\$ 634,616	\$	5,340,295	\$ 9,432,335	\$ 7,308,198